Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor

Journal of Immunotherapy

Volumn 23, Issue 3, 2000, Pages 332-343

  Beecham, E Jeffrey ^a   Ortiz Pujols, Shiara ^a   Junghans, Richard P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Cancer gene therapy; Carcinoembryonic antigen; Cytotoxic T lymphocyte; Immunoglobulin T cell receptor; Lymphokine activated killer cell

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIBODY; CYTOKINE; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL KILLING; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 0034034214     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200005000-00006     Document Type: Article

References (32)

1. Cohen PA, Hwu P, Rosenberg SA. Adoptive cellular immunotherapy and gene therapy. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996, pp 721-47.
2. Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T cell receptor derived C regions. Biochem Biophys Res Commun 1987;149:960-8.
3. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cells receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-8.
4. Goverman J, Gomez S, Segesman K, et al. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 1990;60:929-38.
5. Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 1991;64:1037-46.
6. Eshhar Z, Waks T, Gross G, Schindler D. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the or subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-4.
7. Hwu P, Shafer G, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor chain. J Exp Med 1993;178:361-6.
8. + T lymphocytes armed with universal T-cell receptors. Blood 1994;84:2878-89.
9. Becker MLB, Near R, Mudgett-Hunter M, et al. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 1989;58:911-21.
10. Moritz D, Wells W, Mattern J, Groner B. Cytotoxic T lymphocytes with drafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91:4318-22.
11. Weijtens MEM, Willemsen R, Valerio D, Stam K, Bolhuis R. Single chain Ig-γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996;157:836-43.
12. Altenschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996;2:1001-8.
13. Yang O, Tran A-C, Kalams S, et al. Lysis of HIV-I-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci USA 1997;94:11478-83.
14. Hombach A, Heuser C, Sircar R, et al. An anti-CD30 chimeric receptor that mediates CD3-independent T-cell activation against Hodgkin's lymphoma cells in the presence ot soluble CD30. Cancer Res 1998;58:1116-19.
15. Hwu P, Yang J, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-73.
16. Restifo NP, Kawakami Y, Marincola F, et al. Molecular mechanisms used by tumors to escape immune recognition: immunogene therapy and the cell biology of the major histocompatibility complex class I. J Immunother 1993;14:182-90.
17. Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of designer T cells against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928-41.
18. Akamatsu Y, Nolan KF, Murphy JC, et al. A single chain immunotoxin from a humanized antibody against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Clin Cancer Res 1998;4:2825-32.
19. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complimentarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55(Suppl):5935-45.
20. Coligan JE, Kruisbeek AM, Margulies DH, et al., eds. Current Protocols in Immunology. St. Louis: John Wiley and Sons, 1998.
21. Niles RM, Wilhelm SA, Steele GD, et al. Isolation and characterization of an undifferentiated human colon cancer cell line (MIP-101). Cancer Invest 1987;5:545-52.
22. Thomas P, Gangopadhyay A, Steele G, et al. The effect of transfection of the CEA gene in the metastatic behavior of the human colorectal cancer cell line MIP-101. Cancer Lett 1995;92:59-66.
23. Ballas ZK, Rasmussen W, Van Otegham JK. Lymphokine activated killer cells. II. delineation of distinct murine LAK-precursor subpopulations. J Immunol 1987;138:1647-52.
24. Sawada H, Abo T, Sugawara S, Kumagai K. Prerequisite for the induction of lymphokine activated killer cells from T lymphocytes. J Immunol 1988;140:3668-73.
25. Yamamoto RS, Coss J, Vayuvegula B, et al. Generation of stimulated activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma. J Immunol Methods 1991;137:225-35.
26. Toribio ML, De Landazuri MO, Lopez-Botet M. Induction of natural killer-like cytotoxicity in cultured human thymocytes. Eur J Immunol 1983;13:964.
27. Havele C, Bleackley RC, Paetkau V. Conversion of specific to non-specific cytotoxic T lymphocytes. J Immunol 1986;137:1448.
28. Burns GF, Triglia T, Werkmeister JA. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and anomolous killer cells. J Immunol 1984;133:1656.
29. Damle NK, Doyle LV, Bradley EC. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 1986;137:2814.
30. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressmg tumor cells - a mechanism of immune evasion? Nat Med 1996;2:1361-6.
31. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
32. Torre-Amione G, Beauchamp RD, Koeppen H, et al. A highly immunogenic tumor transfected with a murine TGF cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990;87:1486-90.